Generics - North America, Reproductive

Filter

Current filters:

North AmericaReproductive

Popular Filters

Generic launches by Mylan, Stada Arz and Dr Reddy's

27-06-2013

US copy drugs maker Mylan (NYSE: MYL) has launched norethindrone tablets USP, 0.35 the generic version…

Dr Reddy's LaboratoriesEuropeGenericsLamictal XRMarkets & MarketingMen's HealthMicronorMylan LaboratoriesNeurologicalNorth AmericaReproductiveSTADA ArzneimittelViagra

Watson gets FDA final approval for generic Actos; negative news on Prochieve appeal

29-10-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) said on Friday that it has launched a generic…

ActosDiabetesGenericsLegalMylan LaboratoriesNorth AmericaProchieveRegulationReproductiveTakeda PharmaceuticalsWatson Pharmaceuticals

USA FDA approves ANDAs for Plan B One-Step and Trandate

16-07-2012

Watson Pharmaceuticals (NYSE: WPI) says its subsidiary Watson Laboratories approval from the US Food…

Cardio-vascularGenericsNorth AmericaPar PharmaceuticalsPlan B One-StepRegulationReproductiveTeva Pharmaceutical IndustriesTrandateWatson Pharmaceuticals

Warner Chilcott sues Watson over Lo Loestrin; Actavis debuts generic Requip

20-05-2012

Ireland-headquartered Warner Chilcott (Nasdaq: WCRX) has filed suit against USA-based Watson Pharmaceuticals…

ActavisGenericsGlaxoSmithKlineLegalLo LoestrinMarkets & MarketingNeurologicalNorth AmericaPatentsRegulationReproductiveRequip XLWarner ChilcottWatson Pharmaceuticals

Watson confirms patent challenge to Bayer’s Beyaz

13-02-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) on Friday confirmed that its subsidiary, Watson…

BayerBeyazGenericsNorth AmericaPatentsRegulationReproductiveWatson Pharmaceuticals

Watson settles with Janssen over Ortho Tri-Cyclen LO

08-02-2012

US generic drugmaker Watson Pharmaceutical (NYSE: WPI) says that its subsidiary, Watson Laboratories,…

GenericsJanssenJohnson & JohnsonLegalNorth AmericaPatentsReproductiveWatson PharmaceuticalsWomen's Health

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top